Advertisement
Advertisement
XLO
Xilio Therapeutics, Inc. Common Stock
8.53
USDSponsored
+0.18
+2.15%
Mar 25, 15:58 UTC -4
Closed
Pre-Market
8.63
+0.10
+1.16%
XLO Earnings Reports
Positive Surprise Ratio
XLO beat 11 of 18 last estimates.
61%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Xilio Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 23, 2026, XLO reported earnings of 0.81 USD per share (EPS) for Q4 25, beating the estimate of -1.69 USD, resulting in a 147.74% surprise. Revenue reached 13.69 million, compared to an expected 8.04 million, with a 70.23% difference. The market reacted with a -0.59% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were Xilio Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Xilio Therapeutics, Inc. Common Stock reported EPS of $0.81, beating estimates by 147.74%, and revenue of $13.69M, 70.23% above expectations.
How did the market react to Xilio Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -0.59%, changed from $0.54 before the earnings release to $0.54 the day after.
When is Xilio Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Xilio Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Xilio Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement